IL10 and cancer: Although the reasons for the limited clinical efficacy of IL-12 in cancer patients remain incompletely understood, several immunosuppressive mechanisms including a Th1 to Th2 shift due to increased IL-10 production and diminished IFN-γ production after repetitive treatments with IL-12 could be involved [24, 25].